NATCO Pharma receives favourable FDA inspection report for Chennai API unitNATCO Pharma receives favourable FDA inspection report for Chennai API unit

Introduction

Leading pharmaceutical company received U.S. FDA Establishment Inspection Report for its Chennai API unit, classified as Voluntary Action Indicated with seven observations noted.

Also Read: Airtel launches AI-powered solution to prevent OTP fraud; stock gains momentum

Share price movement of NATCO Pharma

On February 13, 2026, Natco Pharma Ltd opened at ₹825.20, down 1.71% from its previous close of ₹839.90. The stock reached a high of ₹834.00 (0.71%) and a low of ₹818.35 (−2.55%). By 2:05 PM, it traded at ₹824.90, a 1.79% decrease, with a market cap of ₹14,774.77 crore.

NATCO API Unit FDA Report

NATCO Pharma Limited informed that the U.S. FDA inspected its API unit in Manali, Chennai, from November 17 to 21, 2025, issuing seven observations in Form-483 during the inspection.

The company has received the Establishment Inspection Report (EIR) from the U.S. FDA for the API unit. The FDA classified the inspection outcome as Voluntary Action Indicated (VAI).

The EIR confirms NATCO Pharma’s API unit compliance status as per U.S. FDA standards. The company has recorded this information for regulatory and public disclosure purposes.

Stock performance of NATCO Pharma for period of 1 week, 6 months, and 1 year

Natco Pharma Ltd delivered a 1.98% return over the past week, declined 3.96% in the past 6 months, and fell 13.9% over the past 1 year.

Also Read: Ashok Leyland posts 5.2% PAT growth, shares rally 3%

Shareholding pattern of NATCO Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	49.50%	49.50%	49.60%
FII	15.20%	14.10%	15.50%
DII	5.40%	5.90%	5.80%
Public	30.00%	30.60%	29.10%

About NATCO Pharma

NATCO Pharma Ltd (NATCOPHARM) is a research-driven pharmaceutical company developing, manufacturing, and marketing complex products, including finished dosage formulations, active pharmaceutical ingredients, and contract manufacturing services.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs